Before Invest
GILEAD SCIENCES, INC. logo

GILEAD SCIENCES, INC.

GILD
Biological Products No Disgnostic Substances
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 14 years
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		LTMDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Revenues:
                  
Product sales
-
-
-
-
Royalty revenues
-
-
-
-
Royalty, contract and other revenues
-
-
-
-
Total revenues
30,457
29,443
28,754
27,116
Costs and expenses:
                  
Cost of goods sold
6,216
6,234
6,251
6,498
Research and development expenses
6,065
5,799
5,907
5,718
Acquired in-process research and development expenses
11,999
1,024
4,663
1,155
In-process research and development impairments
2,150
590
4,180
50
Selling, general and administrative expenses
6,523
5,774
6,091
6,090
Total costs and expenses
32,954
19,421
27,092
19,511
Operating income
(2,497)
10,022
1,662
7,605
Interest expense
(998)
(1,024)
(977)
(944)
Other (income) expense, net
1,539
798
6
198
Income before income taxes
(1,955)
9,796
690
6,859
Income tax (benefit) expense
1,285
1,286
211
1,247
Net income
-
8,510
480
5,613
Net loss attributable to noncontrolling interest
-
0
0
(52)
Net income attributable to Gilead
$ (3,240)
$ 8,510
$ 480
$ 5,665
Basic earnings per share attributable to Gilead (in dollars per share)
$ (2.61)
$ 6.84
$ 0.38
$ 4.54
Diluted earnings per share attributable to Gilead (in dollars per share)
(2.65)
6.78
0.38
4.5
Shares used in basic earnings per share attributable to Gilead calculation (in shares)
1,243
1,244
1,247
1,248
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)
1,243
1,255
1,255
1,258
Cash dividends declared per share
-
-
-
-